Intra-Cellular Therapies, Inc. – NASDAQ:ITCI
Founder-led company
Intra-Cellular Therapies stock price today
$131.87
+47.02
+55.42%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Intra-Cellular Therapies stock price monthly change
+8.60%
month
Intra-Cellular Therapies stock price quarterly change
+8.60%
quarter
Intra-Cellular Therapies stock price yearly change
+15.21%
year
Intra-Cellular Therapies key metrics
Market Cap | 8.85B |
Enterprise value | 5.39B |
P/E | -21.66 |
EV/Sales | 21.64 |
EV/EBITDA | -21.72 |
Price/Sales | 22.15 |
Price/Book | 8.41 |
PEG ratio | -0.97 |
EPS | -1.16 |
Revenue | 512.31M |
EBITDA | -131.53M |
Income | -110.86M |
Revenue Q/Q | 52.92% |
Revenue Y/Y | 65.73% |
Profit margin | -102.86% |
Oper. margin | -105.82% |
Gross margin | 91.79% |
EBIT margin | -105.82% |
EBITDA margin | -25.68% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIntra-Cellular Therapies stock price history
Intra-Cellular Therapies stock forecast
Intra-Cellular Therapies financial statements
Average Price Target
$87.75
Potential downside: -33.45%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 110.12M | -42.78M | -38.85% |
|---|---|---|---|
| Sep 2023 | 125.81M | -24.25M | -19.28% |
| Dec 2023 | 131.50M | -28.57M | -21.73% |
| Mar 2024 | 144.86M | -15.24M | -10.52% |
| Jun 2023 | 713602000 | 106.51M | 14.93% |
|---|---|---|---|
| Sep 2023 | 717664000 | 116.98M | 16.3% |
| Dec 2023 | 728295000 | 136.87M | 18.79% |
| Mar 2024 | 747036000 | 147.53M | 19.75% |
| Jun 2023 | -36.80M | 94.74M | 8.58M |
|---|---|---|---|
| Sep 2023 | -25.27M | -20.16M | 2.58M |
| Dec 2023 | -2.06M | 47.42M | 3.00M |
| Mar 2024 | -34.11M | 16.17M | 9.98M |
Intra-Cellular Therapies alternative data
| Aug 2023 | 561 |
|---|---|
| Sep 2023 | 561 |
| Oct 2023 | 561 |
| Nov 2023 | 561 |
| Dec 2023 | 561 |
| Jan 2024 | 561 |
| Feb 2024 | 561 |
| Mar 2024 | 610 |
| Apr 2024 | 610 |
| May 2024 | 610 |
| Jun 2024 | 610 |
| Jul 2024 | 610 |
Intra-Cellular Therapies other data
98.28%
+13.84%
of ITCI is owned by hedge funds
230
+30
79.85M
+11.15M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 303644 |
| Feb 2024 | 0 | 143101 |
| Mar 2024 | 0 | 135646 |
| Jun 2024 | 0 | 24462 |
| Aug 2024 | 0 | 305712 |
| Nov 2024 | 0 | 41583 |
| Dec 2024 | 0 | 102697 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MATES SHARON director, officer.. | Common Stock | 51,697 | $12.73 | $658,103 | ||
Sale | MATES SHARON director, officer.. | Common Stock | 50,163 | $84.07 | $4,216,953 | ||
Sale | MATES SHARON director, officer.. | Common Stock | 1,534 | $84.69 | $129,914 | ||
Option | MATES SHARON director, officer.. | Stock Option (right to buy) | 51,697 | $12.73 | $658,103 | ||
Option | MATES SHARON director, officer.. | Common Stock | 51,000 | $12.73 | $649,230 | ||
Sale | MATES SHARON director, officer.. | Common Stock | 27,667 | $85.62 | $2,368,904 | ||
Sale | MATES SHARON director, officer.. | Common Stock | 23,333 | $86.01 | $2,006,755 | ||
Option | MATES SHARON director, officer.. | Stock Option (right to buy) | 51,000 | $12.73 | $649,230 | ||
Option | HALSTEAD MICHAEL officer: President | Common Stock | 18,714 | $36.89 | $690,359 | ||
Sale | HALSTEAD MICHAEL officer: President | Common Stock | 13,371 | $88.17 | $1,178,921 |
| Patent |
|---|
Grant Utility: Salts and crystals Filling date: 26 Sep 2018 Issue date: 13 Sep 2022 |
Application Filling date: 22 Feb 2022 Issue date: 8 Sep 2022 |
Application Filling date: 21 Aug 2020 Issue date: 8 Sep 2022 |
Grant Utility: Organic compounds Filling date: 20 Jul 2018 Issue date: 30 Aug 2022 |
Grant Utility: Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyr- rolo[1,2,3-de]quinoxaline Filling date: 7 Oct 2019 Issue date: 9 Aug 2022 |
Grant Utility: Organic compounds Filling date: 20 Jul 2018 Issue date: 5 Jul 2022 |
Application Filling date: 16 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 10 Apr 2020 Issue date: 16 Jun 2022 |
Application Filling date: 4 Apr 2020 Issue date: 16 Jun 2022 |
Grant Utility: Amorphous solid dispersions Filling date: 3 Oct 2017 Issue date: 17 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Sharon Mates (1953) Co-Founder, Chairman, Chief Executive Officer & Pres | $1,480,000 |
| Mr. Mark Neumann (1963) EVice President & Chief Commercial Officer | $973,300 |
| Mr. Michael I. Halstead J.D. (1973) Executive Vice President, Gen. Counsel & Sec. | $849,930 |
| Dr. Suresh K. Durgam M.D. (1969) Senior Vice President & Chief Medical Officer | $730,360 |
Mr. Lawrence J. Hineline CPA, CPA (1956) Senior Vice President of Fin., Chief Financial Officer, Treasurer & Assistant Sec. | $706,210 |
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
The Right Play On Intra-Cellular Therapies
Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster
Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)
-
What's the price of Intra-Cellular Therapies stock today?
One share of Intra-Cellular Therapies stock can currently be purchased for approximately $131.87.
-
When is Intra-Cellular Therapies's next earnings date?
Unfortunately, Intra-Cellular Therapies's (ITCI) next earnings date is currently unknown.
-
Does Intra-Cellular Therapies pay dividends?
No, Intra-Cellular Therapies does not pay dividends.
-
How much money does Intra-Cellular Therapies make?
Intra-Cellular Therapies has a market capitalization of 8.85B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 86.4% to 464.37M US dollars.
-
What is Intra-Cellular Therapies's stock symbol?
Intra-Cellular Therapies, Inc. is traded on the NASDAQ under the ticker symbol "ITCI".
-
What is Intra-Cellular Therapies's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Intra-Cellular Therapies?
Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Intra-Cellular Therapies's key executives?
Intra-Cellular Therapies's management team includes the following people:
- Dr. Sharon Mates Co-Founder, Chairman, Chief Executive Officer & Pres(age: 72, pay: $1,480,000)
- Mr. Mark Neumann EVice President & Chief Commercial Officer(age: 62, pay: $973,300)
- Mr. Michael I. Halstead J.D. Executive Vice President, Gen. Counsel & Sec.(age: 52, pay: $849,930)
- Dr. Suresh K. Durgam M.D. Senior Vice President & Chief Medical Officer(age: 56, pay: $730,360)
- Mr. Lawrence J. Hineline CPA, CPA Senior Vice President of Fin., Chief Financial Officer, Treasurer & Assistant Sec.(age: 69, pay: $706,210)
-
Is Intra-Cellular Therapies founder-led company?
Yes, Intra-Cellular Therapies is a company led by its founder Dr. Sharon Mates.
-
How many employees does Intra-Cellular Therapies have?
As Jul 2024, Intra-Cellular Therapies employs 610 workers.
-
When Intra-Cellular Therapies went public?
Intra-Cellular Therapies, Inc. is publicly traded company for more then 11 years since IPO on 7 Jan 2014.
-
What is Intra-Cellular Therapies's official website?
The official website for Intra-Cellular Therapies is intracellulartherapies.com.
-
Where are Intra-Cellular Therapies's headquarters?
Intra-Cellular Therapies is headquartered at 430 East 29th Street, New York, NY.
-
How can i contact Intra-Cellular Therapies?
Intra-Cellular Therapies's mailing address is 430 East 29th Street, New York, NY and company can be reached via phone at +64 6 440 9333.
-
What is Intra-Cellular Therapies stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Intra-Cellular Therapies in the last 12 months, the avarage price target is $87.75. The average price target represents a -33.45% change from the last price of $131.87.
Intra-Cellular Therapies company profile:
Intra-Cellular Therapies, Inc.
intracellulartherapies.comExchange:
NASDAQ
Full time employees:
610
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
430 East 29th Street
New York, NY 10016
New York, NY 10016
CIK: 0001567514
ISIN: US46116X1019
CUSIP: 46116X101
